Search research articles
Contact Us
Filters
Showing results (1-10 of 82) with videos related to
Page
of 9
Sort By:
Hematology/Oncology Clinics of North America
|
August 1, 1995
Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide
E S Kleinerman
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy
|
November 1, 1993
Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy
T Asano, E S Kleinerman
Journal of Immunology (Baltimore, Md. : 1950)
|
March 1, 1990
Innate resistance to herpes simplex virus infection. Human lymphocyte and monocyte inhibition of viral replication
M Sarmiento, E S Kleinerman
Cancer Biotherapy & Radiopharmaceuticals
|
June 14, 2000
Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for resectable melanoma in patients who were at high risk for relapse: an update
M A Gianan, E S Kleinerman
Cancer Practice
|
January 1, 1995
Administration of liposomal MTP-PE by the local physician: the role of the research nurse
J B Gano, E S Kleinerman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 1, 1984
Lymphokine-activated human blood monocytes destroy tumor cells but not normal cells under cocultivation conditions
I J Fidler, E S Kleinerman
Lymphokine and Cytokine Research
|
August 1, 1991
Antitumor activity of TNF-alpha, IL-1, and IFN-gamma against three human osteosarcoma cell lines
S F Jia, E S Kleinerman
Oncology Nursing Forum
|
June 1, 1995
Liposomal MTP-PE: a promising new biologic response modifier
J B Gano, E S Kleinerman
Cancer Immunology, Immunotherapy : CII
|
January 1, 1994
Liposome-encapsulated muramyl tripeptide up-regulates monocyte chemotactic and activating factor gene expression in human monocytes at the transcriptional and post-transcriptional levels
T Asano, K Matsushima, E S Kleinerman
Cancer Treatment and Research
|
January 1, 1993
Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma
E S Kleinerman, M Maeda, N Jaffe
Page
of 9
Search research articles
Search
Showing results (1-10 of 82) with videos related to
Sort By:
Page
of 9
Hematology/Oncology Clinics of North America
|
August 1, 1995
Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide
E S Kleinerman
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy
|
November 1, 1993
Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy
T Asano, E S Kleinerman
Journal of Immunology (Baltimore, Md. : 1950)
|
March 1, 1990
Innate resistance to herpes simplex virus infection. Human lymphocyte and monocyte inhibition of viral replication
M Sarmiento, E S Kleinerman
Cancer Biotherapy & Radiopharmaceuticals
|
June 14, 2000
Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for resectable melanoma in patients who were at high risk for relapse: an update
M A Gianan, E S Kleinerman
Cancer Practice
|
January 1, 1995
Administration of liposomal MTP-PE by the local physician: the role of the research nurse
J B Gano, E S Kleinerman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 1, 1984
Lymphokine-activated human blood monocytes destroy tumor cells but not normal cells under cocultivation conditions
I J Fidler, E S Kleinerman
Lymphokine and Cytokine Research
|
August 1, 1991
Antitumor activity of TNF-alpha, IL-1, and IFN-gamma against three human osteosarcoma cell lines
S F Jia, E S Kleinerman
Oncology Nursing Forum
|
June 1, 1995
Liposomal MTP-PE: a promising new biologic response modifier
J B Gano, E S Kleinerman
Cancer Immunology, Immunotherapy : CII
|
January 1, 1994
Liposome-encapsulated muramyl tripeptide up-regulates monocyte chemotactic and activating factor gene expression in human monocytes at the transcriptional and post-transcriptional levels
T Asano, K Matsushima, E S Kleinerman
Cancer Treatment and Research
|
January 1, 1993
Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma
E S Kleinerman, M Maeda, N Jaffe
Page
of 9